Macquarie Group
PACB icon

Macquarie Group’s Pacific Biosciences PACB Stock Holding History

Macquarie Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,638,910
Closed -$24.9M – 2067
2024
Q1 		$24.9M Buy
6,638,910
+1,667,406
+34% +$9.76M 0.03% 619
2023
Q4 		$48.8M Buy
4,971,504
+723,785
+17% +$5.92M 0.06% 438
2023
Q3 		$35.5M Buy
4,247,719
+173,555
+4% +$1.98M 0.04% 501
2023
Q2 		$54.2M Buy
4,074,164
+60,547
+2% +$736K 0.06% 403
2023
Q1 		$46.5M Buy
4,013,617
+1,093
+0% +$10.9K 0.06% 442
2022
Q4 		$32.8M Sell
4,012,524
-10,748
-0.3% -$92.6K 0.04% 578
2022
Q3 		$23.4M Buy
4,023,272
+48,995
+1% +$281K 0.03% 650
2022
Q2 		$17.6M Buy
3,974,277
+133,251
+3% +$810K 0.02% 731
2022
Q1 		$35K Buy
3,841,026
+1,941,270
+102% +$22.4M 0.03% 625
2021
Q4 		$38.9M Buy
1,899,756
+1,692,396
+816% +$40.8M 0.03% 579
2021
Q3 		$5.3M Sell
207,360
-3,590
-2% -$106K ﹤0.01% 1095
2021
Q2 		$7.38M Buy
210,950
+20,743
+11% +$603K 0.01% 1018
2021
Q1 		$6.34M Sell
190,207
-889,419
-82% -$31.1M 0.01% 849
2020
Q4 		$28M Buy
1,079,626
+1,077,750
+57,449% +$18.3M 0.04% 438
2020
Q3 		$19K Hold
1,876
– – ﹤0.01% 2175
2020
Q2 		$6K Buy
+1,876
New +$6.39K ﹤0.01% 2332
2016
Q4 		– Sell
-316,779
Closed -$2.84M – 1569
2016
Q3 		$2.84M Sell
316,779
-316,871
-50% -$2.65M 0.01% 863
2016
Q2 		$4.46M Buy
+633,650
New +$5.79M ﹤0.01% 903

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group's PACB Position: Q2 2024 in Review

Macquarie Group sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 6,638,910 shares — an estimated $24.9M sold.

Macquarie Group first reported a position in PACB in Q2 2016 and held it in 18 quarters. The position peaked at $54.2M in Q2 2023. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • Macquarie Group reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 6,638,910 Pacific Biosciences shares in Q2 2024, an estimated $24.9M.
  • Macquarie Group first reported a position in Pacific Biosciences in Q2 2016 and held it in 18 quarters.
  • Macquarie Group's Pacific Biosciences position peaked at $54.2M in Q2 2023.
  • 228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.